Type 1 Diabetes Consortium The T1D Consortium is working to qualify islet autoimmunity antibodies as prognostic biomarkers to be used in the development of t
Quantitative Medicine Program In 2008, C-Path embarked on a visionary journey, setting the stage for innovation in model-informed drug development (MIDD). A piv
Translational Therapeutics Accelerator The Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is a global drug discovery and development
Regulatory Science Program The Regualtory Science (RegSci) Program was founded in 2020 to lead regulatory strategy development and supports regulatory submis
Predictive Safety Testing Consortium Although companies have developed newer methods to test drug safety, these are not globally accepted by the FDA or EMA as proof of
Rare Disease Clinical Outcome Assessment Consortium The Rare Disease Clinical Outcome Assessment Consortium enables precompetitive, multi-stakeholder collaboration aimed at identifyi
Rare Disease Cures Accelerator-Data and Analytics Platform The Data and Analytics Platform RDCA-DAP houses integrated patient-level data from diverse sources, including clinical trials, lon
Patient-Reported Outcome Consortium PRO measures assess one or more aspects of a patient’s health status based on information gathered directly from the patient, wi
Polycystic Kidney Disease Outcomes Consortium Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a debilitating genetic disease affecting more than 600,000 Americans and 1
